2026-01-10 - Analysis Report
Here's a breakdown of the SDGR (Schrodinger Inc) stock analysis, based on the information you provided:

**0. Summary of Data:**

*   **Ticker:** SDGR (Schrodinger Inc)
*   **Company Overview:** Schrodinger Inc. is a company likely involved in computational chemistry and drug discovery software and services.

**1. Return Rate Comparison (SDGR vs. S&P 500 - VOO):**

*   **SDGR Cumulative Return:** -52.82%
*   **VOO (S&P 500) Cumulative Return:** 65.98%
*   **Divergence:** -118.7 (Relative Divergence: 2.2)

**Analysis:** SDGR has significantly underperformed the S&P 500. The divergence is substantial, indicating a large difference in returns. The relative divergence of 2.2 suggests that the current divergence is near the low end of its historical range.

**Alpha, Beta Analysis:**

| Year       | CAGR   | MDD    | Alpha    | Beta | Cap(B) |
|------------|--------|--------|----------|------|--------|
| 2021-2023  | -57.0% | 52.9%  | -58.0%   | 1.8  | 2.6    |
| 2022-2024  | 6.0%   | 46.6%  | -13.0%   | 1.8  | 1.4    |
| 2023-2025  | -4.0%  | 46.6%  | -66.0%   | 1.8  | 1.3    |

*   **CAGR:** Schrodinger has had negative Compound Annual Growth Rates over the periods examined.
*   **MDD:** Maximum Drawdown is substantial, indicating significant price volatility and potential for loss.
*   **Alpha:** The negative Alpha figures show that the stock has consistently underperformed its expected return based on its risk (Beta).
*   **Beta:** The Beta is consistently above 1, indicating that the stock is more volatile than the market (S&P 500).
*   **Cap(B):** Market capitalization has decreased over the periods.

**2. Recent Stock Price Fluctuations:**

*   **Current Close:** 18.61
*    **Last-market:** {'price': 18.39, 'previousClose': 18.61, 'change': -1.18}
*   **5-day SMA:** 18.53
*   **20-day SMA:** 18.18
*   **60-day SMA:** 18.69

**Analysis:** The 5-day SMA is slightly above the 20-day SMA, which could be a short-term bullish sign. The 60-day SMA is a bit higher than the current price, suggesting the stock is currently trading slightly below its medium-term average. The last-market data shows a small price decrease of -1.18.

**3. Technical Indicators:**

*   **Market Risk Indicator (MRI):** 0.7 (Medium Investment)
*   **RSI:** 61.75 (Indicates slightly overbought conditions, though not extreme)
*   **PPO:** 0.51 (Positive, suggesting short-term bullish momentum)
*   **Hybrid Signal:** cash_0%_Buy 90% of cash (5 shares - Safe - MRI:0.80) (Cash Ratio: 0% on 2026-01-05) (Suggests a buy signal with low cash position)
*   **Recent Divergence Change:** 1.5 (+) (Indicates a short-term upward trend)
*   **Expected Return (%):** -2839.2 (Very negative, indicating a significant expected loss compared to long-term investment in S&P 500)

**Analysis:** The MRI suggests a medium level of investment risk. The RSI indicates the stock is close to being overbought. The PPO suggests some positive momentum. The Hybrid Signal suggests a buy recommendation based on these indicators, with a small purchase. However, the expected return is extremely negative, which is a very concerning factor.

**4. Recent News & Significant Events:**

*   **[2026-01-09] Is Schrödinger’s TuneLab AI Integration Reshaping the Investment Case For SDGR?** - This suggests potential for future growth due to AI integration.
*   **[2026-01-09] Eli Lilly in pact with Schrödinger in AI-related drug discovery** - Positive news, indicating partnerships and potential revenue streams.
*   **[2026-01-07] SDGR: UBS Initiates Coverage with Neutral Rating | SDGR Stock Ne** - Neutral rating suggests a balanced view from UBS.
*   **[2025-12-22] BofA Upgrades Schrödinger (SDGR) to Buy After Strategic Pivot to Software** - Positive news suggesting a change in strategy is viewed favorably.
*   **[2026-01-07] UBS Initiates Coverage of Schrödinger (SDGR) with Neutral Recommendation** - Reinforces the neutral stance from UBS.
*   **[2026-01-09] Schrödinger, Inc.'s (NASDAQ:SDGR) Earnings Haven't Escaped The Attention Of Investors** - General news mentioning investor scrutiny of earnings.

**Analysis:** Recent news is a mixed bag. The AI integration and Eli Lilly partnership are positive catalysts. However, the UBS's neutral rating tempers the positive news. BofA's upgrade is a strong bullish signal.

**4-2. Analyst Opinions:**

*   **Consensus:** Buy (~1.60)
*   **Target Price (avg/high/low):** 25.00 / 32.00 / 18.00

**Analysis:** The analyst consensus is "Buy," with an average target price considerably higher than the current price. This suggests analysts believe the stock is undervalued.

**5. Recent Earnings Analysis:**

| 날짜       | EPS     | 매출      |
|------------|---------|-----------|
| 2025-11-05 | -0.45   | 0.05 B$   |
| 2025-08-06 | -0.59   | 0.05 B$   |
| 2025-05-07 | -0.82   | 0.06 B$   |
| 2024-11-12 | -0.52   | 0.04 B$   |
| 2025-11-05 | -0.52   | 0.04 B$   |

**Analysis:** Earnings per share (EPS) are consistently negative, indicating the company is not currently profitable. Revenue figures are also relatively low.

**6. Financial Information (Revenue & Profitability, Capital & Profitability):**

**Revenue and Profitability:**

| Quarter      | Revenue   | Profit Margin |
|--------------|-----------|---------------|
| 2025-09-30   | $0.05B    | 51.61%        |
| 2025-06-30   | $0.05B    | 47.77%        |
| 2025-03-31   | $0.06B    | 52.26%        |
| 2024-12-31   | $0.09B    | 72.61%        |
| 2024-09-30   | $0.04B    | 50.24%        |

**Capital and Profitability:**

| Quarter      | Equity    | ROE    |
|--------------|-----------|--------|
| 2025-09-30   | $0.32B    | -10.21% |
| 2025-06-30   | $0.34B    | -12.59% |
| 2025-03-31   | $0.37B    | -16.01% |
| 2024-12-31   | $0.42B    | -9.54%  |
| 2024-09-30   | $0.45B    | -8.49%  |

**Analysis:** While the profit margins are relatively high, the revenue figures are still low. The negative Return on Equity (ROE) is consistent with the negative EPS, reinforcing the lack of profitability. Furthermore, equity is decreasing, which can be a concerning sign for a company's long-term health.

**7. Comprehensive Analysis (Summary):**

*   **Performance:** SDGR has significantly underperformed the S&P 500.
*   **Financials:** The company is currently unprofitable, with negative EPS and ROE. While profit margins are high, revenue is low, and equity is decreasing.
*   **Technicals:** Technical indicators present a mixed picture. Recent upward momentum is seen in PPO and divergence changes, but the RSI is approaching overbought levels.
*   **News & Analyst Sentiment:** News is mixed, with positive developments in AI partnerships and strategic shifts, but neutral ratings from some analysts. The analyst consensus is "Buy," suggesting potential for future growth, with high target prices.
*   **Risk:** The MRI indicates a medium investment risk. However, the negative expected return suggests a high risk of long-term losses relative to the S&P 500.
*   **Overall:** SDGR presents a high-risk, high-reward investment opportunity. The company is currently unprofitable, but positive developments in AI and partnerships could lead to future growth. The significant divergence from the S&P 500 and the extremely negative expected return are major red flags. Investors should weigh the potential for future growth against the significant financial risks before investing in SDGR.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.